Alkaloids

Colchicine reduces the risk of COVID-19-related complications

Retrieved on: 
Saturday, January 23, 2021
Organic compounds, Drugs, Acetamides, Alkaloids, Colchicine, Chemical compounds, Coronavirus disease

The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo.

Key Points: 
  • The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo.
  • This major scientific discovery makes colchicine the worlds first oral drug that could be used to treat non-hospitalized patients with COVID-19.
  • Treating patients at risk of complications with colchicine as soon as the diagnosis of COVID-19 is confirmed by PCR reduces their risk of developing a severe form of the disease and, consequently, reduces the number of hospitalizations.
  • It was designed to determine whether colchicine could reduce the risk of severe complications associated with COVID-19.

Colchicine reduces the risk of COVID-19-related complications

Retrieved on: 
Saturday, January 23, 2021
Organic compounds, Drugs, Acetamides, Alkaloids, Colchicine, Chemical compounds, Coronavirus disease

The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo.

Key Points: 
  • The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo.
  • This major scientific discovery makes colchicine the worlds first oral drug that could be used to treat non-hospitalized patients with COVID-19.
  • Treating patients at risk of complications with colchicine as soon as the diagnosis of COVID-19 is confirmed by PCR reduces their risk of developing a severe form of the disease and, consequently, reduces the number of hospitalizations.
  • It was designed to determine whether colchicine could reduce the risk of severe complications associated with COVID-19.

BerGenBio (BGBIO): Progressing towards key inflection points

Retrieved on: 
Thursday, December 17, 2020
Protein kinase inhibitors, Acute myeloid leukemia, Myelodysplastic syndrome, Bemcentinib, Clinical medicine, Orphan drugs, Chemical substances, Health, Alkaloids

BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020.

Key Points: 
  • BerGenBio has presented two positive datasets for its lead asset bemcentinib in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) at ASH 2020.
  • We still forecast the NDA submission for this indication in 2023 (FDA fast-track has been granted).
  • We continue to value BerGenBio at NOK5.16bn or NOK59.1 per share based on a risk-adjusted NPV analysis.
  • The key drivers are bemcentinib in second-line NSCLC (peak sales $1.2bn, NOK40.7/share) and AML (peak sales $588m, NOK13.3/share) plus COVID-19 opportunity (NOK5.9/share).

EQS-News: Relief Therapeutics and NeuroRx Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure

Retrieved on: 
Monday, December 7, 2020
Coronavirus disease, Occupational safety and health, Zoonoses, Health sciences, Health, Medicine, Organofluorides, Alkaloids, Intensive care medicine, COVID-19 drug repurposing research, COVID-19 drug development

There is currently no FDA-approved drug that has shown efficacy in patients who are already in the Intensive Care Unit (ICU) with Respiratory Failure.

Key Points: 
  • There is currently no FDA-approved drug that has shown efficacy in patients who are already in the Intensive Care Unit (ICU) with Respiratory Failure.
  • In addition to the ongoing phase 2b/3 trial, more than 200 patients with Critical COVID-19 and respiratory failure have been treated in an FDA-approved, Expanded Access Protocol (EAP) for RLF-100(TM).
  • These patients were unable to enter the phase 2b/3 randomized trial due to severe comorbidities (such as organ transplant, recent heart attack, or cancer).
  • In the EAP, of the 90 patients who have reached 28 days post-treatment, 72% have survived to day 28.

Colchicine shows promise as a treatment for at-home COVID-19 patients

Retrieved on: 
Sunday, November 29, 2020
Health sciences, Clinical trials, Health, Clinical research, Pharmaceutical industry, Organic compounds, Occupational safety and health, Alkaloids, Colchicine, Coronavirus disease, Placebo-controlled study, Patient recruitment

We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.

Key Points: 
  • We aim at completing patient recruitment in this large study within the next month and hope that colchicine will reduce the risk of COVID-19 complications.
  • COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study run out of Canada, the United States, Europe, South America, and South Africa.
  • It aims to determine if colchicine can reduce the risk of serious complications linked to COVID-19.
  • This is one of the few current large-scale studies of COVID-19 in which non-hospitalized patients can participate.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
Saturday, August 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.

Early, in-hospital treatment with colchicine reduces the odds of future cardiovascular problems by 48% in people who have just survived a heart attack

Retrieved on: 
Saturday, August 29, 2020
RTT, Drugs, Health, Acetamides, Alkaloids, Colchicine, Polypharmacy, Myocardial infarction, Colcot

Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.

Key Points: 
  • Considering that patients receive long-term treatment with multiple drugs after a heart attack, prediction of those unlikely to benefit from a specific medication is necessary to decrease polypharmacy.
  • In addition to these meaningful results from COLCOT, colchicine is also being evaluated in the COLCORONA clinical trial.
  • Time-to-treat initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT).
  • Cost-Effectiveness of Low-Dose Colchicine after Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT), Eur Heart J Qual Care Clin Outcomes.

Nearly Half of Americans Surveyed Willing to Consider Participating in Generic Drug Trials for COVID-19 Treatments Despite Testing Notification Delays up to Six Days

Retrieved on: 
Sunday, August 23, 2020
Medical specialties, Health, Clinical medicine, RTT, Arthritis, Rheumatology, Alkaloids, Colchicine, Pericarditis, Gout, Clinical trial, Familial Mediterranean fever

Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."

Key Points: 
  • Each of those studies concluded that we need quality, robust clinical trials like COLCORONA to definitively change clinical practice for colchicine usage."
  • Non-hospitalized patients over 40 years old, diagnosed with COVID-19, can participate for free by calling the hotline at 1-877-536-6837.
  • Colchicine is a generic, orally administered anti-inflammatory medication that is currently indicated for the management of pericarditis, gout, and familial Mediterranean fever.
  • It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.

Dr. Reddy's Laboratories Announces the Launch of Colchicine Tablets USP, 0.6 mg in the U.S. Market

Retrieved on: 
Friday, June 12, 2020
Biotechnology, FDA, Pharmaceutical, Health, Articles, Organic compounds, Drugs, RTT, Acetamides, Alkaloids, Colchicine, Dr. Reddy's Laboratories, Generic drug, IQVIA

Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).

Key Points: 
  • Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the launch of Colchicine Tablets USP, a therapeutic equivalent generic version of Colcrys (colchicine) Tablets, 0.6 mg, approved by the U.S. Food and Drug Administration (USFDA).
  • The Colcrys brand and generic market had U.S. sales of approximately $491 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health*.
  • Dr. Reddys Colchicine is available in 0.6 mg tablets in bottle count sizes of 30s and 100s.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.

Montreal Heart Institute Colcorona Study receives grant from the COVID-19 Therapeutics Accelerator via the Bill & Melinda Gates Foundation to investigate cheap, readily available drug

Retrieved on: 
Tuesday, May 12, 2020
Computer security software, Organic compounds, Drugs, Acetamides, Alkaloids, Colchicine, RTT, MHI, Alwaleed Philanthropies, Montreal Heart Institute, Avast, Mark Zuckerberg

MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.

Key Points: 
  • MONTREAL, May 12, 2020 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) Research Center today announced a 3-million-dollar grant from the COVID-19 Therapeutics Accelerator for its innovative ColCorona COVID-19 clinical trial.
  • The hypothesis is that colchicine may prevent the phenomenon of major inflammatory storm responsible for severe complications seen in patients with COVID-19.
  • This is one of the few current studies of COVID-19 infection in which non-hospitalized individuals can participate.
  • COVID-19 Therapeutics Accelerator donors include the Bill & Melinda Gates Foundation, Wellcome, Mastercard, U.K. Department for International Development, Chan Zuckerberg Initiative, Michael & Susan Dell Foundation, Avast, Zhang Yiming, Alwaleed Philanthropies, EQT and Madonna.